FINNENCE ▪ THE WIRE FILE
THE WIRE · № 75707
News■ Unclear/unknown
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A new biosimilar G-CSF launch affects oncology supportive-care competition but the parent is private.
Biosimilar entry pressures oncology supportive care
CATALYST TO WATCH
Reimbursement adoption and payer coverage
MAIN RISK
Private parent limits investable read-through
FULL DISPATCH
FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology,...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks2026-10-12 12:09 UTC
Wisner Baum Lawsuit Alleges Syngenta Failed to Warn of Atrazine's Cancer Risks2026-10-12 12:09 UTC
→CORRELATIONshares Healthcare
Another Healthcare Increase Is Coming. Are Employers Watching the Spending Closely Enough?2026-10-12 12:09 UTC
Another Healthcare Increase Is Coming. Are Employers Watching the Spending Closely Enough?2026-10-12 12:09 UTC
←CORRELATIONshares Healthcare
Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study2026-10-12 10:00 UTC
Spiro Medical Treats First Asthma Patient With Neuromodulation in IDE Feasibility Study2026-10-12 10:00 UTC
←CORRELATIONshares Healthcare
New drug shows multiple improvements for people with Parkinson's disease2026-10-12 10:21 UTC
New drug shows multiple improvements for people with Parkinson's disease2026-10-12 10:21 UTC
←CORRELATIONshares Healthcare
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
City Thera targets $175 million IPO to advance RNA drugs2026-10-12 10:23 UTC
←CORRELATIONshares Healthcare
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
Viatris: Improved Confidence Drives M&A Action Again (NASDAQ:VTRS)2026-10-12 10:29 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.